Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia working party of the European Society for blood and marrow transplantation (SAAWP of EBMT)

A Correction to this article was published on 20 December 2021

This article has been updated

Abstract

Aplastic anemia is a relatively rare but potentially fatal disorder, with a reported higher incidence in developing countries in comparison to the West. There are significant variations in epidemiological as well as etiological factors of bone marrow failure syndromes in the developing countries in comparison to the developed world. Furthermore, the management of bone marrow failure syndromes in resource constraint settings has significant challenges including delayed diagnosis and referral, limited accessibility to healthcare facilities, treatment modalities as well as limitations related to patients who require allogeneic stem cell transplantation. Here we will provide a review of the available evidence related to specific issues of aplastic anemia in the developing countries and we summarize suggested recommendations from the Eastern Mediterranean blood and bone marrow transplantation (EMBMT) group and the severe aplastic anemia working party of the European Society of blood and marrow transplantation (SAAWP of EBMT) related to the diagnosis and therapeutic options in countries with restricted resources.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1
Fig. 2: Proposed treatment algorithm of AA in resource-constrained countries.

Change history

References

  1. Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172:187–207.

    PubMed  Article  Google Scholar 

  2. Kojima S. Why is the incidence of aplastic anemia higher in Asia? Expert Rev Hematol. 2017;10:277–9.

    CAS  PubMed  Article  Google Scholar 

  3. Ally M, Magesa P, Luzzatto L. High frequency of acquired aplastic anemia in Tanzania. Am J Hematol. 2019;94:E86–8.

    PubMed  Article  Google Scholar 

  4. Peslak SA, Olson T, Babushok DV. Diagnosis and treatment of aplastic anemia. Curr Treat Options Oncol. 2017;18:70.

    PubMed  PubMed Central  Article  Google Scholar 

  5. Camitta BM, Storb R, Thomas ED. Aplastic anemia (first of two parts): pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med. 1982;306:645–52.

    CAS  PubMed  Article  Google Scholar 

  6. Savage SA, Viard M, O’HUigin C, Zhou W, Yeager M, Li SA, et al. Genome-wide Association Study Identifies HLA-DPB1 as a significant risk factor for severe aplastic anemia. Am J Hum Genet. 2020;106:264–71.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. Dolberg OJ, Levy Y. Idiopathic aplastic anemia: diagnosis and classification. Autoimmun Rev. 2014;13:569–73.

    PubMed  Article  Google Scholar 

  8. Gadalla SM, Savage SA. Telomere biology in hematopoiesis and stem cell transplantation. Blood Rev. 2011;25:261–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  9. Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. Haematologica. 2008;93:489–92.

    PubMed  Article  Google Scholar 

  10. Montané E, Ibáñez L, Vidal X, Ballarín E, Puig R, García N, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93:518–23.

    PubMed  Article  Google Scholar 

  11. Ahmed P, Chaudhry QUN, Satti TM, Mahmood SK, Ghafoor T, Shahbaz N, et al. Epidemiology of aplastic anemia: a study of 1324 cases. Hematology. 2020;25:48–54.

    CAS  PubMed  Article  Google Scholar 

  12. Akram Z, Ahmed P, Kajigaya S, Satti TM, Satti HS, Chaudhary QUN, et al. Epidemiological, clinical and genetic characterization of aplastic anemia patients in Pakistan. Ann Hematol. 2019;98:301–12.

    CAS  PubMed  Article  Google Scholar 

  13. Rehman S, Saba N, Naz M, Ahmed P, Munir S, Sajjad S, et al. Single-nucleotide polymorphisms of FAS and FASL genes and risk of idiopathic aplastic anemia. Immunol Investig. 2018;47:484–91.

    CAS  Article  Google Scholar 

  14. Rehman S, Ahmed P, Saba N, Munir S, Sajjad S, Satti TM, et al. Association of GSTM1 and GSTT1 deletion polymorphisms with Pakistani aplastic anemia patients and controls and meta-analysis. Ann Hematol. 2015;94:1965–71.

    CAS  PubMed  Article  Google Scholar 

  15. Mahapatra M, Singh PK, Agarwal M, Prabhu M, Mishra P, Seth T, et al. Epidemiology, clinico-haematological profile and management of aplastic anaemia: AIIMS experience. J Assoc Physicians India. 2015;63 (3 Suppl):30–5.

    CAS  PubMed  Google Scholar 

  16. Prihartono N, Kriebel D, Woskie S, Thetkhathuek A, Sripaung N, Padungtod C, et al. Risk of aplastic anemia and pesticide and other chemical exposures. Asia Pac J Public Health. 2011;23:369–77.

    PubMed  Article  Google Scholar 

  17. Young NS, Issaragrasil S, Chieh CW, Takaku F. Aplastic anaemia in the Orient. Br J Haematol. 1986;62:1–6.

    CAS  PubMed  Article  Google Scholar 

  18. Wang L, Liu H. Pathogenesis of aplastic anemia. Hematology. 2019;24:559–66.

    PubMed  Article  Google Scholar 

  19. Mary JY, Baumelou E, Guiguet M. Epidemiology of aplastic anemia in France: a prospective multicentric study. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood. 1990;75:1646–53.

    CAS  Google Scholar 

  20. Shallis RM, Ahmad R, Zeidan AM. Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts. Eur J Haematol. 2018;101:711–20.

    CAS  PubMed  Article  Google Scholar 

  21. Issaragrisil S, Kaufman DW, Anderson T, Chansung K, Leaverton PE, Shapiro S, et al. The epidemiology of aplastic anemia in Thailand. Blood. 2006;107:1299–307.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. Yong AS, Goh AS, Rahman J, Menon J, Purushothaman V. Epidemiology of aplastic anemia in the state of Sabah, Malaysia. Med J Malaysia. 1998;53:59–62.

    CAS  PubMed  Google Scholar 

  23. Ahamed M, Anand M, Kumar A, Siddiqui MKJ. Childhood aplastic anaemia in Lucknow, India: incidence, organochlorines in the blood and review of case reports following exposure to pesticides. Clin Biochem. 2006;39:762–6.

    CAS  PubMed  Article  Google Scholar 

  24. Jeong DC, Chung NG, Kang HJ, Koo HH, Kook H, Kim SK, et al. Epidemiology and clinical long-term outcome of childhood aplastic anemia in Korea for 15 years: retrospective study of the Korean Society of Pediatric Hematology Oncology (KSPHO). J Pediatr Hematol Oncol. 2011;33:172–8.

    PubMed  Article  Google Scholar 

  25. Arewa OP, Akinola NO. Survival in primary a plastic anaemia; experience with 20 cases from a tertiary hospital in Nigeria. Afr Health Sci. 2009;9:290–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Moore CA, Krishnan K. Aplastic Anemia, in StatPearls. 2021, StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.: Treasure Island (FL).

  27. Adil S, Kakepoto GN, Khurshid M, Burney IA. Epidemiological features of aplastic anaemia in Pakistan. J Pak Med Assoc. 2001;51:443.

    CAS  PubMed  Google Scholar 

  28. Ehrlich P. Ueber einem Fall von Anämie mit Bemerkungen über regenerative Veränderungen des Knochenmarks. Charité-Annalen. 1888;13:301–9.

    Google Scholar 

  29. Smith MT. Overview of benzene-induced aplastic anaemia. Eur J Haematol. 1996;60:107–10.

    CAS  Google Scholar 

  30. Aksoy M. Benzene as a leukemogenic and carcinogenic agent. Am J Ind Med. 1985;8:9–20.

    CAS  PubMed  Article  Google Scholar 

  31. Cudillo L. Aplastica anemia and viral hepatitis. Mediterr J Hematol Infect Dis. 2009;1:e2009026.

    PubMed  PubMed Central  Google Scholar 

  32. Alter BP. Aplastic anemia, pediatric aspects. Oncologist. 1996;1:361–6.

    CAS  PubMed  Article  Google Scholar 

  33. McCahon E, Tang K, Rogers PC, McBride ML, Schultz KR. The impact of Asian descent on the incidence of acquired severe aplastic anaemia in children. Br J Haematol. 2003;121:170–2.

    PubMed  Article  Google Scholar 

  34. Chen C-H, Ferreira JC, Joshi AU, Stevens MC, Li S-J, Hsu JH-M, et al. Novel and prevalent non-East Asian ALDH2 variants; implications for global susceptibility to aldehydes’ toxicity. EBioMedicine. 2020;55:102753.

    PubMed  PubMed Central  Article  Google Scholar 

  35. Rehman S, Saba N, Khalilullah, Munir S, Ahmed P, Mehmood T. The frequency of HLA class I and II alleles in Pakistani patients with aplastic anemia. Immunol Investig. 2009;38:812–9.

    CAS  Article  Google Scholar 

  36. Lee KA, Kim SH, Woo HY, Hong YJ, Cho HC. Increased frequencies of glutathione S-transferase (GSTM1 and GSTT1) gene deletions in Korean patients with acquired aplastic anemia. Blood. 2001;98:3483–5.

    CAS  PubMed  Article  Google Scholar 

  37. Sleijfer S, Lugtenburg P. Aplastic anaemia: a review. Neth J Med. 2003;61:157–63.

    CAS  PubMed  Google Scholar 

  38. Dutta A, De R, Dolai TK, Mitra PK, Halder A. Comparative study of environmental factors and different addictions in aplastic anaemia patients in Eastern India. J Blood Disord Symptoms Treat. 2019;8:2015–8.

    Google Scholar 

  39. Taj M, Shah T, Aslam SK, Zaheer S, Nawab F, Shaheen S, et al. Environmental determinants of aplastic anemia in Pakistan: a case-control study. J Public Health. 2016;24:453–60.

    PubMed  Article  Google Scholar 

  40. Marsh JCW. Aplastic anemia: what’s in the environment? Blood. 2006;107:1250.

    CAS  Article  Google Scholar 

  41. Akram Z, Ahmed P, Kajigaya S, Satti TM, Satti HS, Gutierrez-Rodrigues F, et al. Epidemiological, clinical and genetic characterization of aplastic anemia patients in Pakistan. Ann Hematol. 2019;98:301–12.

    CAS  PubMed  Article  Google Scholar 

  42. Kook H, Chung NG, Kang HJ, Im HJ. Acquired aplastic anemia in Korean children: treatment guidelines from the Bone Marrow Failure Committee of the Korean Society of Pediatric Hematology Oncology. Int J Hematol. 2016;103:380–6.

    PubMed  Article  Google Scholar 

  43. Ramzan M, Yadav SP, Zafar MS, Dinand V, Sachdeva A. Outcome of pediatric acquired aplastic anemia: a developing world experience. Pediatr Hematol Oncol. 2014;31:29–38.

    PubMed  Article  Google Scholar 

  44. Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telomeropathies. Blood. 2014;124:2775–83.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. Alter BP. Inherited bone marrow failure syndromes: considerations pre- and posttransplant. Blood. 2017;130:2257–64.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. Narayanan S. Managing anaemia in bone marrow failure syndromes. Curr Opin Support Palliat Care. 2018;12:538–41.

    PubMed  Article  Google Scholar 

  47. Young NS. Current concepts in the pathophysiology and treatment of aplastic anemia. Hematol Am Soc Hematol Educ Program. 2013;2013:76–81.

    Article  Google Scholar 

  48. Höchsmann B, Moicean A, Risitano A, Ljungman P, Schrezenmeier H. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant. 2013;48:168–73.

    PubMed  Article  Google Scholar 

  49. Han W. Health care system reforms in developing countries. J Public Health Res. 2012;1:199.

    PubMed  PubMed Central  Article  Google Scholar 

  50. Valdez JM, Scheinberg P, Young NS, Walsh TJ. Infections in patients with aplastic anemia. Semin Hematol. 2009;46:269–76.

    PubMed  Article  Google Scholar 

  51. Young NS. Aplastic Anemia. N Engl J Med. 2018;379:1643–56.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  52. Zhang Y, Wu L, Mo W, Zhou M, Li Y, Chen X, et al. Comparable outcomes of first-line hematopoietic stem cell transplantation from unrelated and matched sibling donors in adult patients with aplastic anemia: a retrospective single-center study. Biol Blood Marrow Transplant. 2019;25:1567–75.

    PubMed  Article  Google Scholar 

  53. Marsh JC, Risitano AM, Mufti GJ. The case for upfront HLA-matched unrelated donor hematopoietic stem cell transplantation as a curative option for adult acquired severe aplastic anemia. Biol Blood Marrow Transplant. 2019;25:e277–84.

    PubMed  Article  Google Scholar 

  54. Xu LP, Jin S, Wang SQ, Xia LH, Bai H, Gao SJ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol. 2017;10:25.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  55. Chaudhry QUN, Iftikhar R, Satti TM, Mahmood SK, Ghafoor T, Shamshad GU, et al. Outcome of fludarabine-based conditioning in high-risk aplastic anemia patients undergoing matched related donor transplantation: a single-center study from Pakistan. Biol Blood Marrow Transplant. 2019;25:2375–82.

    CAS  PubMed  Article  Google Scholar 

  56. Jubelirer SJ. The benefit of the neutropenic diet: fact or fiction? Oncologist. 2011;16:704.

    PubMed  PubMed Central  Article  Google Scholar 

  57. Quillen K, Wong E, Scheinberg P, Young NS, Walsh TJ, Wu CO, et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica. 2009;94:1661–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. Garg A, Gupta A, Mishra A, Singh M, Yadav S, Nityanand S. Role of granulocyte transfusions in combating life-threatening infections in patients with severe neutropenia: experience from a tertiary care centre in North India. PloS ONE. 2018;13:e0209832.

    PubMed  PubMed Central  Article  Google Scholar 

  59. Kallen ME, Dulau-Florea A, Wang W, Calvo KR. Acquired and germline predisposition to bone marrow failure: Diagnostic features and clinical implications. Semin Hematol. 2019;56:69–82.

    PubMed  Article  Google Scholar 

  60. Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376:1540–50.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. Cle DV, Atta EH, Dias DSP, Lima CBL, Bonduel M, Sciuccati G, et al. Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study. Ann Hematol. 2018;97:2039–46.

    CAS  PubMed  Article  Google Scholar 

  62. Lum SH, Grainger JD. Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Des Devel Ther. 2016;10:2833–43.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  63. Al-Ghazaly J, Al-Dubai W, Al-Jahafi AK, Abdullah M, Al-Hashdi A. Cyclosporine monotherapy for severe aplastic anemia: a developing country experience. Ann Saudi Med. 2005;25:375–9.

    PubMed  PubMed Central  Article  Google Scholar 

  64. Maschan A, Bogatcheva N, Kryjanovskii O, Shneider M, Litvinov D, Mitiushkina T, et al. Results at a single centre of immunosuppression with cyclosporine A in 66 children with aplastic anaemia. Br J Haematol. 1999;106:967–70.

    CAS  PubMed  Article  Google Scholar 

  65. Mandal PK, Baul S, Dolai TK, De R, Chakrabarti P. Outcome of cyclosporine monotherapy in patients of aplastic anemia: experience of a Tertiary Care Hospital in Eastern India. Indian J Hematol Blood Transfus. 2017;33:144–7.

    PubMed  Article  Google Scholar 

  66. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365:430–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  67. Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood. 2012;119:5391–6.

    CAS  PubMed  Article  Google Scholar 

  68. Risitano AM, Perna F. Aplastic anemia: immunosuppressive therapy in 2010. Pediatr Rep. 2011;3:14–7.

    CAS  Article  Google Scholar 

  69. Feng X, Scheinberg P, Biancotto A, Rios O, Donaldson S, Wu C, et al. In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia. Haematologica. 2014;99:1433–40.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  70. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144:206–16.

    CAS  PubMed  Article  Google Scholar 

  71. Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, et al. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2018;103:212–20.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  72. Ecsedi M, Lengline É, Knol-Bout C, Bosman P, Eikema D-J, Afanasyev B, et al. Use of eltrombopag in aplastic anemia in Europe. Ann Hematol. 2019;98:1341–50.

    PubMed  Article  Google Scholar 

  73. Konishi A, Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, et al. Evaluation of eltrombopag in patients with aplastic anemia in real-world experience. Leuk Res Rep. 2019;11:11–3.

    PubMed  PubMed Central  Google Scholar 

  74. Zhu Y, Gao Q, Hu J, Liu X, Guan D, Zhang F. Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis. BMC Immunol. 2020;21:10.

    PubMed  PubMed Central  Article  Google Scholar 

  75. Dufour C, Pillon M, Sociè G, Rovò A, Carraro E, Bacigalupo A, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol. 2015;169:565–73.

    PubMed  Article  Google Scholar 

  76. Dufour C, Pillon M, Passweg J, Socie G, Bacigalupo A, Franceschetto G, et al. Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2014;99:1574–81.

    PubMed  PubMed Central  Article  Google Scholar 

  77. Georges GE. Consider allogeneic bone marrow transplantation for older, fitpatients with aplastic anemia. Biol Blood Marrow Transplant. 2019;25:e69–70.

    PubMed  Article  Google Scholar 

  78. Sheth VS, Potter V, Gandhi SA, Kulasekararaj AG, de Lavallade H, Muus P, et al. Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years. Blood Adv. 2019;3:3070–9.

    PubMed  PubMed Central  Article  Google Scholar 

  79. Zhang YY, Mo WJ, Zuo YY, Zhou M, Zhang XH, Wang Y, et al. Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: a retrospective multicenter cohort study. Clin Transplant. 2020;34:e13810.

    PubMed  Article  Google Scholar 

  80. Geng C, Liu X, Chen M, Yang C, Han B. Comparison of frontline treatment with intensive immunosuppression therapy and HLA-haploidentical hematopoietic stem cell transplantation for young patients with severe aplastic anemia—a meta analysis. Leuk Res. 2020;88:106266.

    CAS  PubMed  Article  Google Scholar 

  81. Prata PH, Eikema DJ, Afansyev B, Bosman P, Smiers F, Diez-Martin JL, et al. Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. Bone Marrow Transplant. 2020;55:1050–58.

    CAS  PubMed  Article  Google Scholar 

  82. Ciceri F, Lupo-Stanghellini M, Korthof E. Haploidentical transplantation in patients with acquired aplastic anemia. Bone Marrow Transplant. 2013;48:183–5.

    CAS  PubMed  Article  Google Scholar 

  83. Luo CJ, Chen J, Wang JM, Qin X, Zhang BH, Zhu H, et al. Alternative donor HSCT for 109 children with acquired severe aplastic anemia: a single center retrospective analysis. Zhonghua Xue Ye Xue Za Zhi. 2020;41:128–31.

    CAS  PubMed  Google Scholar 

  84. Yoshida N, Kojima S. Updated guidelines for the treatment of acquired aplastic anemia in children. Curr Oncol Rep. 2018;20:67.

    PubMed  Article  Google Scholar 

  85. Dufour C, Veys P, Carraro E, Bhatnagar N, Pillon M, Wynn R, et al. Similar outcome of upfront‐unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. Br J Haematol. 2015;171:585–94.

    CAS  PubMed  Article  Google Scholar 

  86. Yue C, Ding Y, Gao Y, Li L, Pang Y, Liu Z, et al. Cotransplantation of haploidentical hematopoietic stem cells and allogeneic bone marrow-derived mesenchymal stromal cells as a first-line treatment in very severe aplastic anemia patients with refractory infections. Eur J Haematol. 2018;100:624–9.

    CAS  PubMed  Article  Google Scholar 

  87. Lu Y, Sun RJ, Zhao YL, Xiong M, Cao XY, Zhang JP, et al. Unmanipulated haploidentical hematopoietic stem cell transplantation achieved outcomes comparable with matched unrelated donor transplantation in young acquired severe aplastic anemia. Biol Blood Marrow Transplant. 2018;24:1881–7.

    PubMed  Article  Google Scholar 

  88. Li Y, Duan F, Xiao H, Wu X, Wang S, Xu D, et al. Therapeutic outcomes of haploidentical allogeneic hematopoietic stem cell transplantation in patients with severe aplastic anemia: a multicenter study. Transplantation. 2018;102:1724–31.

    PubMed  Article  Google Scholar 

  89. Kim H, Lee KH, Sohn SK, Kim I, Kim SH, Park Y, et al. Effect of stem cell source and dose on allogeneic hematopoietic stem cell transplantation in adult patients with idiopathic aplastic anemia: data from the korean aplastic anemia trials. Acta Haematol. 2020;143:232–43.

    CAS  PubMed  Article  Google Scholar 

  90. Bacigalupo A, Socie G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuehrer M, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica. 2012;97:1142–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  91. Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110:1397–400.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  92. Kumar R, Kimura F, Ahn KW, Hu Z-H, Kuwatsuka Y, Klein JP, et al. Comparing outcomes with bone marrow or peripheral blood stem cells as graft source for matched sibling transplants in severe aplastic anemia across different economic regions. Biol Blood Marrow Transplant. 2016;22:932–40.

    PubMed  PubMed Central  Article  Google Scholar 

  93. Morton J, Hutchins C, Durrant S. Granulocyte–colony-stimulating factor (G-CSF)–primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF–mobilized peripheral blood stem cells. Blood. 2001;98:3186–91.

    CAS  PubMed  Article  Google Scholar 

  94. Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2014;20:1711–6.

    PubMed  Article  Google Scholar 

  95. Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941–9.

    CAS  PubMed  Article  Google Scholar 

  96. Aljurf M, Al-Zahrani H, Van Lint M, Passweg J. Standard treatment of acquired SAA in adult patients 18–40 years old with an HLA-identical sibling donor. Bone Marrow Transplant. 2013;48:178–9.

    CAS  PubMed  Article  Google Scholar 

  97. Iftikhar R, Anwer F, Neupane K, Rafae A, Mahmood SK, Ghafoor T, et al. Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies. Blood Rev. 2020;47:100772.

    PubMed  Article  CAS  Google Scholar 

  98. Iftikhar R, Satti TM, Mahmood SK, Ghafoor T, Shamshad GU, Shahbaz N, et al. Comparison of Conventional Cyclophosphamide versus Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched-Related Donor Transplantation. Clin Hematol Int. 2020;2:82–91.

    PubMed  PubMed Central  Article  Google Scholar 

  99. Aljurf M, Zaidi SZ, El Solh H, Hussain F, Ghavamzadeh A, Mahmoud HK, et al. Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report. Bone Marrow Transplant. 2009;43:1–12.

    CAS  PubMed  Article  Google Scholar 

  100. Chen JY, Zheng TL, Zhou T, Hu PW, Huang MJ, Xu X, et al. Human cytomegalovirus prevalence and distribution of glycoprotein B, O genotypes among hospitalized children with respiratory infections in West China, 2009–2014. Trop Med Int Health. 2016;21:1428–34.

    CAS  PubMed  Article  Google Scholar 

  101. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant. 2009;44:453–5.

    CAS  PubMed  Article  Google Scholar 

  102. Burroughs LM, Woolfrey AE, Storer BE, Deeg HJ, Flowers ME, Martin PJ, et al. Success of allogeneic marrow transplantation for children with severe aplastic anaemia. Br J Haematol. 2012;158:120–8.

    PubMed  PubMed Central  Article  Google Scholar 

  103. Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011;118:2351–7.

    CAS  PubMed  Article  Google Scholar 

  104. Vaht K, Goransson M, Carlson K, Isaksson C, Lenhoff S, Sandstedt A, et al. High graft-versus-host disease-free, relapse/rejection-free survival and similar outcome of related and unrelated allogeneic stem cell transplantation for aplastic anemia: a Nationwide Swedish Cohort Study. Biol Blood Marrow Transplant. 2019;25:1970–4.

    PubMed  Article  Google Scholar 

  105. George B, Mathews V, Viswabandya A, Kavitha ML, Srivastava A, Chandy M. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplant. 2007;40:13–8.

    CAS  PubMed  Article  Google Scholar 

  106. Jalili M, Alimoghaddam K, Hamidieh AA, Hamdi A, Jahani M, Bahar B, et al. Hematopoietic stem cell transplantation in patients with severe acquired aplastic anemia: Iranian experience. Int J Hematol-Oncol Stem Cell Res. 2011;5:22–7.

    Google Scholar 

  107. Atta EH, de Sousa AM, Schirmer MR, Bouzas LF, Nucci M, Abdelhay E. Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia. Biol Blood Marrow Transplant. 2012;18:1876–82.

    CAS  PubMed  Article  Google Scholar 

  108. Shin SH, Lee JW. The optimal immunosuppressive therapy for aplastic anemia. Int J Hematol. 2013;97:564–72.

    CAS  PubMed  Article  Google Scholar 

  109. Agarwal M, Jijina F, Shah S, Malhotra P, Damodar S, Ross C. Safety and efficacy of indigenous equine antithymocyte globulin along with cyclosporine in subjects with acquired aplastic anemia. Indian J Hematol Blood Transfus. 2015;31:174–9.

    CAS  PubMed  Article  Google Scholar 

  110. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol. 2006;34:826–31.

    CAS  PubMed  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Raheel Iftikhar.

Ethics declarations

Conflict of interest

The author declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Members on behalf of the Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group, Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP of EBMT) are listed below.

The original online version of this article was revised: In the original version of this article, the given and family names of Amir Ali Hamidieh were incorrectly structured. The name was displayed correctly in all versions at the time of publication.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Iftikhar, R., Ahmad, P., de Latour, R. et al. Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia working party of the European Society for blood and marrow transplantation (SAAWP of EBMT). Bone Marrow Transplant 56, 2518–2532 (2021). https://doi.org/10.1038/s41409-021-01332-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-021-01332-8

Search

Quick links